To the contrary, recent in vivo studies have suggested that SGLT2 inhibition may be an effective means of attenuating hepatocellular [44–46], renal cell [43], and lung cancer [47] growth by an unclear mechanism. The gene discussed is SLC5A2; the disease is lung cancer.